Filing Details

Accession Number:
0001415889-24-005065
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-02-23 17:00:23
Reporting Period:
2024-02-21
Accepted Time:
2024-02-23 17:00:23
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1551152 Abbvie Inc. ABBV Pharmaceutical Preparations (2834) 320375147
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1563545 Azita Saleki-Gerhardt 1 N. Waukegan Road
North Chicago IL 60064
Evp, Chief Operations Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.01 Par Value Acquisiton 2024-02-21 52,870 $58.88 296,814 No 4 M Direct
Common Stock, $0.01 Par Value Disposition 2024-02-21 52,870 $173.71 243,944 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Option (Right to Buy) Disposition 2024-02-21 52,870 $58.88 52,870 $58.88
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2016-02-19 2025-02-18 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock, $0.01 Par Value 2,322 Indirect Profit sharing trust
Common Stock, $0.01 Par Value 3,873 Indirect By spouse
Footnotes
  1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $173.51 to $174.03, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  2. Balance in AbbVie Savings program as of January 31, 2024.
  3. The reporting person disclaims beneficial ownership of all securities held by her spouse.
  4. Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.